Helix BioPharma Engages ITG for Market-Making Services

Helix BioPharma ( (TSE:HBP) ) has shared an announcement.

Helix BioPharma Corp. has engaged Independent Trading Group (ITG) to provide market-making services to enhance the liquidity of its common shares, subject to regulatory approval. This agreement, which involves ITG trading shares on the TSX and other venues, aims to maintain a reasonable market for Helix’s shares, potentially improving the company’s market presence and attractiveness to investors.

More about Helix BioPharma

Helix BioPharma is an oncology company focused on developing innovative therapies to tackle hard-to-treat cancers. The company has a diverse pipeline of drug candidates, including its lead candidate, Tumour Defence Breaker™ L-DOS47, which is in clinical-stage development for treating solid tumors. Helix BioPharma is listed on multiple stock exchanges, including TSX, OTC PINK, and FWB.

YTD Price Performance: -11.80%

Average Trading Volume: 1,930

Technical Sentiment Signal: Strong Buy

Current Market Cap: C$42.42M

For detailed information about HBP stock, go to TipRanks’ Stock Analysis page.